JW (Cayman) Therapeutics Co. Ltd
HKEX:2126.HK
1.37 (HKD) • At close September 20, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2023 Q4 | 2023 Q2 | 2022 Q4 | 2022 Q2 | 2021 Q4 | 2021 Q2 | 2020 Q4 | 2020 Q2 | 2019 Q4 | 2019 Q2 | 2018 Q4 | 2018 Q2 | 2018 Q1 | 2017 Q4 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 86.116 | 87.74 | 79.695 | 66.007 | 30.797 | 0 | -0.847 | 0.847 | 5.081 | 0.402 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 42.71 | 42.927 | 44.07 | 42.876 | 21.752 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 43.406 | 44.813 | 35.625 | 23.131 | 9.045 | 0 | -0.847 | 0.847 | 5.081 | 0.402 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0.504 | 0.511 | 0.447 | 0.35 | 0.294 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 197.085 | 216.531 | 211.931 | 195.887 | 228.888 | 185.509 | 142.949 | 82.266 | 81.851 | 54.256 | 34.027 | 18.997 | 18.997 | 18.997 |
| General & Administrative Expenses
| 61.354 | 78.694 | 88.841 | 90.922 | 96.417 | 105.101 | 150.287 | 81.007 | 47.336 | 25.556 | 6.66 | 5.137 | 5.137 | 5.137 |
| Selling & Marketing Expenses
| 53.028 | 60.168 | 106.43 | 84.447 | 124.556 | 46.176 | 13.268 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 114.382 | 138.862 | 195.271 | 175.369 | 220.973 | 151.277 | 163.555 | 81.007 | 47.336 | 25.556 | 6.66 | 5.137 | 5.137 | 5.137 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -198.663 | -91.559 | -91.559 | -91.559 |
| Operating Expenses
| 443.093 | 434.733 | 459.553 | 455.086 | 434.885 | 282.092 | 1,015.762 | 650.712 | 281.667 | 357.542 | -157.977 | -67.425 | -67.425 | -67.425 |
| Operating Income
| -261.615 | -308.531 | -356.3 | -340.875 | -438.593 | -333.123 | -305.434 | -162.426 | -124.106 | -79.41 | -157.977 | -67.425 | -67.425 | -67.425 |
| Operating Income Ratio
| -3.038 | -3.516 | -4.471 | -5.164 | -14.241 | 0 | 360.607 | -191.766 | -24.426 | -197.537 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| -125.966 | -71.884 | -60.581 | -88.379 | 16.96 | 52.428 | -708.34 | -487.603 | -151.282 | -278.459 | -0.338 | -0.729 | -0.729 | -0.729 |
| Income Before Tax
| -387.581 | -380.415 | -416.881 | -429.254 | -421.633 | -280.695 | -1,013.774 | -650.029 | -275.388 | -357.869 | -158.314 | -68.154 | -68.154 | -68.154 |
| Income Before Tax Ratio
| -4.501 | -4.336 | -5.231 | -6.503 | -13.691 | 0 | 1,196.9 | -767.449 | -54.2 | -890.221 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.338 | 0.729 | 0.729 | 0.729 |
| Net Income
| -387.581 | -380.415 | -416.881 | -429.254 | -421.633 | -280.695 | -1,013.774 | -650.029 | -275.388 | -357.869 | -158.652 | -68.883 | -68.883 | -68.883 |
| Net Income Ratio
| -4.501 | -4.336 | -5.231 | -6.503 | -13.691 | 0 | 1,196.9 | -767.449 | -54.2 | -890.221 | 0 | 0 | 0 | 0 |
| EPS
| -0.94 | -0.93 | -1.01 | -1.05 | -1.04 | -0.71 | -5.11 | -9.96 | -4.24 | -5.51 | -0.42 | -0.18 | -0.18 | -0.18 |
| EPS Diluted
| -0.94 | -0.93 | -1.01 | -1.05 | -1.04 | -0.71 | -5.11 | -9.96 | -4.24 | -5.51 | -0.42 | -0.18 | -0.18 | -0.18 |
| EBITDA
| -225.477 | -267.214 | -323.795 | -305.732 | -414.833 | -323.87 | -297.656 | -156.385 | -118.389 | -76.014 | -153.651 | -66.148 | -66.148 | -66.148 |
| EBITDA Ratio
| -2.618 | -3.046 | -4.063 | -4.632 | -13.47 | 0 | 351.424 | -184.634 | -23.3 | -189.09 | 0 | 0 | 0 | 0 |